Bristol-Myers Squibb

Bristol-Myers Squibb

Verified
Discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals

Launch date
Employees
Market cap
$167.7b
Net debt
$6.8b
Firm valuation
$181.0b (Public information from Aug 2022)
New York City New York (HQ)

Financials

Edit
Revenues, earnings & profits over time
USD2016201720182019202020212022E
Revenues-20.8b22.6b26.1b42.5b46.4b47.1b
% growth--9 %16 %63 %9 %1 %
EBITDA-6.1b7.0b9.9b27.8b30.5b21.8b
% EBITDA margin-30 %31 %38 %65 %66 %46 %
Profit-1.0b5.0b3.4b(9b)7.0b8.4b
% profit margin-5 %22 %13 %(21 %)15 %18 %
EV / revenue-4.9x3.7x7.0x4.1x3.6x3.5x
EV / EBITDA-16.5x11.9x18.3x6.3x5.4x7.6x
R&D budget5.1b5.5b6.0b5.9b---
R&D % of revenue-26 %27 %23 %---

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
N/AN/AIPO
Not yet verified
N/AN/AIPO
N/AGrowth Equity VC
Total Funding-

Recent News about Bristol-Myers Squibb

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
  • Edit
Personal Genome Diagnostics (PGD)
ACQUISITION by LabCorp Dec 2021
TARIS Biomedical
ACQUISITION by Johnson & Johnson Dec 2019
Medarex
ACQUISITION by Bristol-Myers Squibb Jul 2009
Amira Pharmaceuticals
ACQUISITION by Bristol-Myers Squibb Jul 2011
TP Therapeutics
ACQUISITION by Bristol-Myers Squibb Jun 2022
Amylin Pharmaceuticals
ACQUISITION by Bristol-Myers Squibb Jun 2012
iPierian
ACQUISITION by Bristol-Myers Squibb Apr 2014
Celgene
ACQUISITION by Bristol-Myers Squibb Nov 2019
View 41 more